Business Fast > Finance > Chick-fil-A reverses course on controversial decision to pull Side Salad, says it's 'here to stay' FinanceChick-fil-A reverses course on controversial decision to pull Side Salad, says it's 'here to stay'April 3, 2023posted on Apr. 03, 2023 at 12:02 am The popular Side Salad will remain on the menu after Chick-fil-A customers blasted the chicken chain’s decision to remove it last month. READ SOURCE tweet Share on FacebookShare on TwitterShare on LinkedInShare on RedditMorebusinessfastApril 3, 2023previous articleUK efforts to tackle modern slavery are waning, analysis findsnext articleIN PHOTOS: 2023 Autos 4 Autism Car Show – Daily Journal OnlineYou Might Also LikeFinance‘Horrendous’: the ‘ridiculously common’ lies people tell on CVs, and what happens when they are discoveredMarch 1, 2025FinanceGlasgow engineering consultancy becomes employee-ownedFebruary 28, 2025BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-TarFebruary 28, 2025FinanceCan AI help modernise Ireland's healthcare system?February 28, 2025FinanceUrgent deadline for tax credits claimants as DWP to stop benefitsFebruary 27, 2025FinanceShare of jobs paid below UK living wage rises at record rateFebruary 27, 2025Recommended For YouMarketBulls vs. Bears: Nvidia Q4 results divide SA communityMarch 1, 2025MarketIndustryAre electric vehicles truly affordable for India’s middle class?March 1, 2025IndustryTechnologyChina's DeepSeek claims theoretical cost-profit ratio of 545% per dayMarch 1, 2025TechnologyBarclays: Euro area defence spending to impact public finances and GDPMarch 1, 2025US economyHere's where BofA sees Brent oil prices trading at in 2025 and 2026March 1, 2025Retail
Finance‘Horrendous’: the ‘ridiculously common’ lies people tell on CVs, and what happens when they are discoveredMarch 1, 2025
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-TarFebruary 28, 2025
TechnologyChina's DeepSeek claims theoretical cost-profit ratio of 545% per dayMarch 1, 2025Technology